IL6 and neoplasm: Unlike BCC and medulloblastoma, however, cells from solid cancers show a ligand-dependent activation of the HH pathway, although many alternative mechanisms have been described, including autocrine- (i.e., breast, lung and prostate cancer), paracrine- (i.e., colon and pancreatic cancer through both IL-6 and VEGF) and reverse paracrine-dependent HH activation, which is the consequence of soluble factors produced by stromal cells nearby tumor cells [43].